OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy
Christopher P. Vellano, Michael G. White, Miles C. Andrews, et al.
Nature (2022) Vol. 606, Iss. 7915, pp. 797-803
Open Access | Times Cited: 93
Christopher P. Vellano, Michael G. White, Miles C. Andrews, et al.
Nature (2022) Vol. 606, Iss. 7915, pp. 797-803
Open Access | Times Cited: 93
Showing 1-25 of 93 citing articles:
The cancer-immunity cycle: Indication, genotype, and immunotype
Ira Mellman, Daniel S. Chen, Thomas Powles, et al.
Immunity (2023) Vol. 56, Iss. 10, pp. 2188-2205
Open Access | Times Cited: 345
Ira Mellman, Daniel S. Chen, Thomas Powles, et al.
Immunity (2023) Vol. 56, Iss. 10, pp. 2188-2205
Open Access | Times Cited: 345
Embracing cancer complexity: Hallmarks of systemic disease
Charles Swanton, Elsa Bernard, Chris Abbosh, et al.
Cell (2024) Vol. 187, Iss. 7, pp. 1589-1616
Open Access | Times Cited: 146
Charles Swanton, Elsa Bernard, Chris Abbosh, et al.
Cell (2024) Vol. 187, Iss. 7, pp. 1589-1616
Open Access | Times Cited: 146
Sex differences orchestrated by androgens at single-cell resolution
Fei Li, Xudong Xing, Qiqi Jin, et al.
Nature (2024) Vol. 629, Iss. 8010, pp. 193-200
Closed Access | Times Cited: 25
Fei Li, Xudong Xing, Qiqi Jin, et al.
Nature (2024) Vol. 629, Iss. 8010, pp. 193-200
Closed Access | Times Cited: 25
Outcome differences by sex in oncology clinical trials
Ashwin V. Kammula, Alejandro A. Schäffer, Padma Sheila Rajagopal, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 16
Ashwin V. Kammula, Alejandro A. Schäffer, Padma Sheila Rajagopal, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 16
A Review of Current and Pipeline Drugs for Treatment of Melanoma
Nicole Natarelli, Soo Aleman, Isabella Mark, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 2, pp. 214-214
Open Access | Times Cited: 15
Nicole Natarelli, Soo Aleman, Isabella Mark, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 2, pp. 214-214
Open Access | Times Cited: 15
Role of the androgen receptor in melanoma aggressiveness
Marzia Di Donato, Costanza Maria Cristiani, Mariaelena Capone, et al.
Cell Death and Disease (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 2
Marzia Di Donato, Costanza Maria Cristiani, Mariaelena Capone, et al.
Cell Death and Disease (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 2
Bodywide ecological interventions on cancer
Guido Kroemer, Jennifer L. McQuade, Miriam Mérad, et al.
Nature Medicine (2023) Vol. 29, Iss. 1, pp. 59-74
Closed Access | Times Cited: 35
Guido Kroemer, Jennifer L. McQuade, Miriam Mérad, et al.
Nature Medicine (2023) Vol. 29, Iss. 1, pp. 59-74
Closed Access | Times Cited: 35
Immune checkpoint B7-H3 is a therapeutic vulnerability in prostate cancer harboring PTEN and TP53 deficiencies
Wei Shi, Yin Wang, Yuehui Zhao, et al.
Science Translational Medicine (2023) Vol. 15, Iss. 695
Open Access | Times Cited: 30
Wei Shi, Yin Wang, Yuehui Zhao, et al.
Science Translational Medicine (2023) Vol. 15, Iss. 695
Open Access | Times Cited: 30
Cancer cell plasticity and MHC-II–mediated immune tolerance promote breast cancer metastasis to lymph nodes
Pin‐Ji Lei, Ethel R. Pereira, Patrik Andersson, et al.
The Journal of Experimental Medicine (2023) Vol. 220, Iss. 9
Open Access | Times Cited: 27
Pin‐Ji Lei, Ethel R. Pereira, Patrik Andersson, et al.
The Journal of Experimental Medicine (2023) Vol. 220, Iss. 9
Open Access | Times Cited: 27
Effect-directed analysis of androgenic compounds from sewage sludges in China
Tongtong Xiang, Chunzhen Shi, Yunhe Guo, et al.
Water Research (2024) Vol. 256, pp. 121652-121652
Closed Access | Times Cited: 10
Tongtong Xiang, Chunzhen Shi, Yunhe Guo, et al.
Water Research (2024) Vol. 256, pp. 121652-121652
Closed Access | Times Cited: 10
Androgen drives melanoma invasiveness and metastatic spread by inducing tumorigenic fucosylation
Qian Liu, Emma Adhikari, Daniel Lester, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 9
Qian Liu, Emma Adhikari, Daniel Lester, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 9
Sex-dependent effects in the aged melanoma tumor microenvironment influence invasion and resistance to targeted therapy
Yash Chhabra, Mitchell E. Fane, Sneha Pramod, et al.
Cell (2024) Vol. 187, Iss. 21, pp. 6016-6034.e25
Closed Access | Times Cited: 8
Yash Chhabra, Mitchell E. Fane, Sneha Pramod, et al.
Cell (2024) Vol. 187, Iss. 21, pp. 6016-6034.e25
Closed Access | Times Cited: 8
Sex and cancer immunotherapy: Current understanding and challenges
Laura Pala, Tommaso De Pas, Chiara Catania, et al.
Cancer Cell (2022) Vol. 40, Iss. 7, pp. 695-700
Open Access | Times Cited: 30
Laura Pala, Tommaso De Pas, Chiara Catania, et al.
Cancer Cell (2022) Vol. 40, Iss. 7, pp. 695-700
Open Access | Times Cited: 30
Additivity predicts the efficacy of most approved combination therapies for advanced cancer
Haeun Hwangbo, Sarah C. Patterson, Andy Dai, et al.
Nature Cancer (2023) Vol. 4, Iss. 12, pp. 1693-1704
Open Access | Times Cited: 20
Haeun Hwangbo, Sarah C. Patterson, Andy Dai, et al.
Nature Cancer (2023) Vol. 4, Iss. 12, pp. 1693-1704
Open Access | Times Cited: 20
Androgen receptor is a determinant of melanoma targeted drug resistance
Anastasia Samarkina, Markus K. Youssef, Paola Ostano, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 19
Anastasia Samarkina, Markus K. Youssef, Paola Ostano, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 19
From genetic variation to precision medicine
Panagiotis I. Sergouniotis, Tomas Fitzgerald, Ewan Birney
Cambridge Prisms Precision Medicine (2023) Vol. 1
Open Access | Times Cited: 16
Panagiotis I. Sergouniotis, Tomas Fitzgerald, Ewan Birney
Cambridge Prisms Precision Medicine (2023) Vol. 1
Open Access | Times Cited: 16
Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations
Funda Meric‐Bernstam, Michael W. Lloyd, Soner Koc, et al.
Molecular Cancer Therapeutics (2024) Vol. 23, Iss. 7, pp. 924-938
Open Access | Times Cited: 6
Funda Meric‐Bernstam, Michael W. Lloyd, Soner Koc, et al.
Molecular Cancer Therapeutics (2024) Vol. 23, Iss. 7, pp. 924-938
Open Access | Times Cited: 6
A Comprehensive Overview of Small-Molecule Androgen Receptor Degraders: Recent Progress and Future Perspectives
Si Ha, Guoshun Luo, Hua Xiang
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 24, pp. 16128-16154
Closed Access | Times Cited: 24
Si Ha, Guoshun Luo, Hua Xiang
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 24, pp. 16128-16154
Closed Access | Times Cited: 24
Sex and outcomes of patients with microsatellite instability-high andBRAFV600E mutated metastatic colorectal cancer receiving immune checkpoint inhibitors
Vincenzo Nasca, Joseph J. Zhao, Javier Ros, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 2, pp. e010598-e010598
Open Access
Vincenzo Nasca, Joseph J. Zhao, Javier Ros, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 2, pp. e010598-e010598
Open Access
Sex hormones, the anticancer immune response, and therapeutic opportunities
Fabio Conforti, Laura Pala, Diletta Di Mitri, et al.
Cancer Cell (2025) Vol. 43, Iss. 3, pp. 343-360
Open Access
Fabio Conforti, Laura Pala, Diletta Di Mitri, et al.
Cancer Cell (2025) Vol. 43, Iss. 3, pp. 343-360
Open Access
Germline variants in CDKN2A wild‐type melanoma prone families
Gjertrud T. Iversen, Marie Loeng, A. Holth, et al.
Molecular Oncology (2025)
Open Access
Gjertrud T. Iversen, Marie Loeng, A. Holth, et al.
Molecular Oncology (2025)
Open Access
Advances in sex disparities for cancer immunotherapy: unveiling the dilemma of Yin and Yang
Junfu Ma, Yanxin Yao, Ye Tian, et al.
Biology of Sex Differences (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 20
Junfu Ma, Yanxin Yao, Ye Tian, et al.
Biology of Sex Differences (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 20
Tumor-Type Agnostic, Targeted Therapies: BRAF Inhibitors Join the Group
Semir Vranić, Gargi D. Basu, David W. Hall, et al.
Acta Medica Academica (2023) Vol. 51, Iss. 3, pp. 217-231
Open Access | Times Cited: 11
Semir Vranić, Gargi D. Basu, David W. Hall, et al.
Acta Medica Academica (2023) Vol. 51, Iss. 3, pp. 217-231
Open Access | Times Cited: 11
The Clinical, Genomic, and Transcriptomic Landscape of BRAF Mutant Cancers
Suzanne Kazandjian, Emmanuelle Rousselle, Matthew Dankner, et al.
Cancers (2024) Vol. 16, Iss. 2, pp. 445-445
Open Access | Times Cited: 4
Suzanne Kazandjian, Emmanuelle Rousselle, Matthew Dankner, et al.
Cancers (2024) Vol. 16, Iss. 2, pp. 445-445
Open Access | Times Cited: 4
Sexual dimorphism in melanocyte stem cell behavior reveals combinational therapeutic strategies for cutaneous repigmentation
Luye An, Dahihm Kim, Leanne R. Donahue, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 4
Luye An, Dahihm Kim, Leanne R. Donahue, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 4
